Study identifier:D419CR00035
ClinicalTrials.gov identifier:NCT06252753
EudraCT identifier:N/A
CTIS identifier:N/A
An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers
Hepatobiliary Cancers
Phase 4
No
-
All
4490
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
ICON plc
No locations available
Arms | Assigned Interventions |
---|---|
unresectable hepatocellular carcinoma (uHCC) unresectable hepatocellular carcinoma (uHCC) | Other: Durvalumab-based combination therapies in observational study setting Data on patients who initiated durvalumab-based regimens, including STRIDE (Single Tremelimumab Regular Interval Durvalumab), will be collected). Other Name: Imfinzi |
advanced biliary tract cancer (aBTC) advanced biliary tract cancer (aBTC) | Other: Durvalumab-based combination therapies in observational study setting Data on patients who initiated durvalumab-based regimens, including durvalumab + chemotherapy combinations (e.g., Durvalumab + GemCis etc.) will be collected. Other Name: Imfinzi |